Laurus Labs Limited announced on January 23, 2026, that its Nomination and Remuneration Committee (NRC) has approved the grant of a total of 423,125 stock options to eligible employees under its "LAURUS EMPLOYEES STOCK OPTION SCHEME 2016", "LAURUS EMPLOYEES STOCK OPTION SCHEME 2018", and "LAURUS EMPLOYEES STOCK OPTION SCHEME 2021". The grant price for these options is ₹754.50 per option, which is 25% less than the market value on January 22, 2026. These grants are intended to motivate employees and provide them an opportunity to participate in the company's performance. Under the 2016 scheme (Grant-V), 55,500 options were granted to 36 employees. Under the 2018 scheme (Grant-V), 1,74,625 options were granted to 1,119 employees of the company and its subsidiaries. Under the 2021 scheme (Grant-III), 1,93,000 options were granted to 39 employees of the company and its subsidiaries. The effective date for all these grants is July 1, 2025. For the 2016 and 2018 schemes, vesting will occur in three stages: 25% on July 1, 2027 (completion of two years from grant), 25% on July 1, 2028 (completion of three years), and 50% on July 1, 2029 (completion of four years). For the 2021 scheme, vesting will occur in four stages: 25% on July 1, 2027, 25% on July 1, 2028, 25% on July 1, 2029, and 25% on July 1, 2030. Vested options must be exercised within one year of their respective vesting dates, or they will lapse.
